Prompt Agalsidase Alfa Therapy Initiation is Associated with Improved Renal and Cardiovascular Outcomes in a Fabry Outcome Survey Analysis.

Drug Des Devel Ther · 2021 · PMC8379390 · PMID 34429585

Europe PMC DOI

hedged sentence

—

closest p

—

boldest claim

The sentences

may be significantno p-value reported

The results of the current analysis suggest that there may be significant benefits with prompt initiation of agalsidase alfa after symptom onset and/or diagnosis of Fabry disease.

also in 13,097 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.